Another great article found in multiple sclerosis news today by Patricia Inacio, PHD.
Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, will invest up to $330,000 to advance the clinical development of an antibody that was shown to lessen inflammation and nerve cell damage in a multiple sclerosis (MS) mouse model.
The funding will help develop the antibody (a protein the immune system uses to neutralize pathogens such as bacteria and viruses) in order to have properties more similar to those found in humans (a humanized antibody), and to test its therapeutic potential in people with MS.
Read the full article here https://multiplesclerosisnewstoday.com/2018/10/31/national-ms-society-invests-clinical-development-potential-therapy/. There is always hope with research.